Healthcare industry

Prof. Dr. Michael Reth is active in the field of immunology and signalling. He is an experienced scientist who is well aware of the difficulty and the cumbersome nature of deciphering signals and signalling pathways. The Freiburg bioss excellence cluster - the Centre of Biological Signalling Studies - is Reths brainchild. Karin Bundschuh from BioRegio Freiburg spoke with the scientist who works at the Max Planck Institute of Immunobiology and the…

A group of researchers led by Prof. Dr. Frank-Michael Müller from Heidelberg has shown that mould fungi like Aspergillus fumigatus are able to develop biofilms in the lungs and protect themselves against the bodys immune defence system and drugs.

A new Clinical Research Unit at the University of Ulm is to investigate the early inflammation response and the positive impact on the immune system in casualty injuries. The insights gained will be transferred to patients.

The Dr. Ernst Wiethoff Award 2008 for innovative clinical research worth 25000 euros was presented to Jan Münch from the Institute of Virology at the University Hospital of Ulm. Münch discovered a new protein that blocks the HI virus.

Prof. Karin Scharffetter-Kochanek has recently become a member of the renowned Leopoldina Academy of Sciences. In her research the skin has become a model system that serves as the basis for a trans-organ systemic approach looking at the underlying mechanisms and the complex interactions with other organs.

The Comprehensive Infectious Diseases Centre at the University of Ulm was recently presented to the public. The centre is responsible for coordinating the cooperation between specialists in the diagnosis and therapy of complex infectious diseases.

Professor Dr. Christoph Borner from the University of Freiburg and his team are investigating the molecular mechanisms of apoptosis. Their research also provides insights into the medical treatment of cells that do not want to die - cancer cells.

The Lake Constance region offers a broad range of cancer therapies and is home to several institutes and companies that are dealing with cancer research. The BioLAGO biotechnology network offers them a joint platform for co-operation and exchange of information.

Renal cell carcinoma is a rare disease. In addition, the disease is difficult to treat, and the majority of pharmaceutical companies find the development of new drugs for its treatment too financially risky. Their argument: the market is too small to make up for the high development costs. The Tübingen biotech company immatics was courageous enough to do so and will now be rewarded. The immatics scientists have developed a therapy that not only…

Press release - 27/07/2008

White blood cells with 'icing' work far better

Scientists from Heidelberg Munich and Aachen have shown that the adhesion molecules required by leukocytes to adhere to vascular walls depend on sugar chains for effective immune defence reactions to occur. The results could open up new strategies for the treatment of inflammatory processes.

The Chemical Biology graduate school at Constance University was officially opened on 7th May 2008. It was created as part of Germanys excellence initiative and has been training doctoral students since the beginning of April 2008.

Press release - 19/05/2008

Viruses caught red-handed

Prof. Thilo Stehle biochemist at the University of Tübingen wants to capture and accurately study the moment at which a virus binds to a cell. He is hoping that further insights into this process might some time enable the development of drugs.

Sharks can sense a few drops of blood in water. In fact they are able to smell blood in dilutions of as little as one to 10 billion. Is it just sharks or piranhas that have such an acute sense of smell? The answer is no - all fish have a highly developed sense of smell.

The German Cancer Research Centre and the Spanish company Chimera Pharma SL have signed an exclusive licensing and cooperation agreement. The two partners will develop a therapeutic vaccine against cervical cancer.

Immune cells sometimes kick over the traces. This could lead to allergic reactions. At the Freiburg Max Planck Institute of Immunobiology a group of researchers led by Professor Michael Huber is investigating the mechanisms that can prevent this from happening.

Scientists from Mannheim Heidelberg an Freiburg working together in the cooperative research area Vascular Biology have developed a method that can be used to create a human vascular system in mice which stays functional even after several months.

Article - 20/02/2008

Threadworms throughout time

Threadworms are versatile research objects and are excellent models for investigating fundamental evolutionary principles. Researchers at the Max Planck Institute for Developmental Biology use the Caenorhabditis and Pristionchus threadworm genera to study the molecular mechanisms of biodiversity.

Karin Bundschuh of BIOPRO Baden-Württemberg asked Dr. Jens Clausen how these developments should be viewed from an ethical perspective. The bioethicist spent many years studying the status of embryos the ethics of cloning and stem cell research.

Tumours develop sophisticated strategies to escape the immune defence. One of these strategies is the modification of the cells sugar coat. Specific immune cell receptors bind to these sugars thereby preventing the tumour cell from being discovered by the immune system. Medics from the University of Tübingen are investigating the mechanisms involved and are looking for therapeutic targets.

About 500000 people in Germany suffer from dilatative cardiomyopathy DCM. Viral infections are the major cause of this myocardial disease. Its molecular and cellular mechanisms are being investigated in a transregional SFB project at the University of Tübingen.